GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » St Jude Medical Inc (NYSE:STJ) » Definitions » ROA %

St Jude Medical (St Jude Medical) ROA % : 6.73% (As of Sep. 2016)


View and export this data going back to 1977. Start your Free Trial

What is St Jude Medical ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. St Jude Medical's annualized Net Income for the quarter that ended in Sep. 2016 was $848 Mil. St Jude Medical's average Total Assets over the quarter that ended in Sep. 2016 was $12,600 Mil. Therefore, St Jude Medical's annualized ROA % for the quarter that ended in Sep. 2016 was 6.73%.

The historical rank and industry rank for St Jude Medical's ROA % or its related term are showing as below:

STJ's ROA % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -1.93
* Ranked among companies with meaningful ROA % only.

St Jude Medical ROA % Historical Data

The historical data trend for St Jude Medical's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

St Jude Medical ROA % Chart

St Jude Medical Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.34 8.18 7.41 9.80 7.62

St Jude Medical Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.29 3.76 2.99 7.55 6.73

Competitive Comparison of St Jude Medical's ROA %

For the Medical Devices subindustry, St Jude Medical's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


St Jude Medical's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, St Jude Medical's ROA % distribution charts can be found below:

* The bar in red indicates where St Jude Medical's ROA % falls into.



St Jude Medical ROA % Calculation

St Jude Medical's annualized ROA % for the fiscal year that ended in Dec. 2015 is calculated as:

ROA %=Net Income (A: Dec. 2015 )/( (Total Assets (A: Dec. 2014 )+Total Assets (A: Dec. 2015 ))/ count )
=880/( (10193+12900)/ 2 )
=880/11546.5
=7.62 %

St Jude Medical's annualized ROA % for the quarter that ended in Sep. 2016 is calculated as:

ROA %=Net Income (Q: Sep. 2016 )/( (Total Assets (Q: Jun. 2016 )+Total Assets (Q: Sep. 2016 ))/ count )
=848/( (12658+12541)/ 2 )
=848/12599.5
=6.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2016) net income data. ROA % is displayed in the 30-year financial page.


St Jude Medical  (NYSE:STJ) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2016 )
=Net Income/Total Assets
=848/12599.5
=(Net Income / Revenue)*(Revenue / Total Assets)
=(848 / 5996)*(5996 / 12599.5)
=Net Margin %*Asset Turnover
=14.14 %*0.4759
=6.73 %

Note: The Net Income data used here is four times the quarterly (Sep. 2016) net income data. The Revenue data used here is four times the quarterly (Sep. 2016) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


St Jude Medical ROA % Related Terms

Thank you for viewing the detailed overview of St Jude Medical's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


St Jude Medical (St Jude Medical) Business Description

Traded in Other Exchanges
N/A
Address
St Jude Medical Inc was incorporated in Minnesota in 1976. It develops, manufactures and distributes cardiovascular medical devices for the cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's two segments are the Implantable Electronic Systems Division and the Cardiovascular and Ablation Technologies Division. The Company's principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) - tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) - vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, cardiac mapping, navigation and recording systems and ablation systems). Implantable Electronic Systems Division (IESD): IESD is focused on the cardiac rhythm management and neuromodulation therapy areas. Cardiac rhythm management devices include ICDs that provide life-saving therapy to patients suffering from lethal heart conditions, such as sudden cardiac arrest; cardiac resynchronization therapy (CRT) devices to save and improve the lives of patients suffering from heart failure (HF); pacemakers to help patients whose hearts beat too slowly or who suffer from other debilitating cardiac arrhythmias; leads (wires that connect devices to the heart) to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment which are used by physicians and healthcare professionals to program is cardiac rhythm management devices and analyze device data to improve patient management. Neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. The Company's commercialized neurostimulation therapies include spinal cord stimulation (SCS) for the treatment of chronic pain, deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease and peripheral nerve stimulation (PNS) for the treatment of chronic migraine headache. A neurostimulation system typically consists of four components: a pulse generator that produces the electrical current and is implanted under the patient's skin; implanted leads that carry the electrical impulses to the targeted nerve sites; an external patient remote control that enables the patient to control his or her therapy within prescribed ranges; and an external clinician pro
Executives
Jeff Fecho officer: VP, Global Quality ONE ST. JUDE MEDICAL DRIVE ST. PAUL MN 55117
Philip Ebeling officer: VP, Chief Technology Officer INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BLVD., SUITE 1600, GOLDEN VALLEY MN 55416
Donald Zurbay officer: VP Finance and CFO C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Michael A Rocca director C/O LIGAND PHARMACEUTICALS INCORPORATED, 10275 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Barbara B Hill director
Wendy L Yarno director
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
John C Heinmiller officer: Executive Vice President ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
John W Brown director STRYKER CORP, 2725 FAIRFIELD ROAD, KALAMAZOO MI 49002
David C Dvorak director C/O ZIMMER INC, PO BOX 708, WARSAW IN 46580
Michael T Rousseau director, officer: Director, President and CEO ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Eric S Fain officer: Group President ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Joel Becker officer: President, Americas ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Rohan Hoare officer: President - NMD 100 CYBERONICS BLVD, HOUSTON TX 77058